Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida real

Detalhes bibliográficos
Autor(a) principal: Tuon, Felipe Francisco
Data de Publicação: 2021
Outros Autores: Pepes, Allana, Oliveira, Dayana Dos Santos, Zequinao, Tiago, Cruz, June Alisson Westarb, Telles, João Paulo
Tipo de documento: Artigo
Idioma: por
Título da fonte: Brazilian Journal of Health Review
Texto Completo: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/34925
Resumo: Vancomycin serum levels (VSL) were measured to prevent dose-dependent side effects.  However, the cost of VSL is high, therefore in some cases alternative antibacterial treatments, such as linezolid, can be used. The aim of this study was to perform an economic analysis of the cost of linezolid compared to vancomycin plus therapeutic drug monitoring. This is an ecological, retrospective, quantitative study, conducted in a Brazilian public university hospital. The study period was from January 2018 to January 2019.  First part from January/18 - July/18 based on pre-linezolid data (T1) and another after the introduction of linezolid from August/18 - January/19 (T2). A breakeven analysis to vancomycin substitution was performed following 3 scenarios: (i) in all patients, (ii) in critically ill patients with renal failure or (iii) only in patients in hemodialysis. The DDD/1000-patients day, MRSA incidence, costs with VSL, as well as the costs of drugs (vancomycin and linezolid) and infusion kits were evaluated. Vancomycin was substituted in critically ill patients with renal failure from T1 to T2. The incidence of MRSA infections did not vary between T1 and T2. Vancomycin consume maintained constant (p=0.157); while linezolid consuming increased (0 DDD/1000PD versus 33.4 DDD/1000PD; p=0.002). Vancomycin and linezolid costs was lower in T1 than T2 (USD 9202,00 versus 11331,00; p=0.015). Linezolid implementation as a strategy to avoid vancomycin plus VSL was not cost-effective in critically ill patients with renal failure. More studies are needed to understand if linezolid implementation may be cost-effective in different scenarios.
id BJRH-0_136d75d3bf0f16adf74ccb9265d06a53
oai_identifier_str oai:ojs2.ojs.brazilianjournals.com.br:article/34925
network_acronym_str BJRH-0
network_name_str Brazilian Journal of Health Review
repository_id_str
spelling Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida realVancomycinLinezolidAntimicrobial StewardshipEconomy.Vancomycin serum levels (VSL) were measured to prevent dose-dependent side effects.  However, the cost of VSL is high, therefore in some cases alternative antibacterial treatments, such as linezolid, can be used. The aim of this study was to perform an economic analysis of the cost of linezolid compared to vancomycin plus therapeutic drug monitoring. This is an ecological, retrospective, quantitative study, conducted in a Brazilian public university hospital. The study period was from January 2018 to January 2019.  First part from January/18 - July/18 based on pre-linezolid data (T1) and another after the introduction of linezolid from August/18 - January/19 (T2). A breakeven analysis to vancomycin substitution was performed following 3 scenarios: (i) in all patients, (ii) in critically ill patients with renal failure or (iii) only in patients in hemodialysis. The DDD/1000-patients day, MRSA incidence, costs with VSL, as well as the costs of drugs (vancomycin and linezolid) and infusion kits were evaluated. Vancomycin was substituted in critically ill patients with renal failure from T1 to T2. The incidence of MRSA infections did not vary between T1 and T2. Vancomycin consume maintained constant (p=0.157); while linezolid consuming increased (0 DDD/1000PD versus 33.4 DDD/1000PD; p=0.002). Vancomycin and linezolid costs was lower in T1 than T2 (USD 9202,00 versus 11331,00; p=0.015). Linezolid implementation as a strategy to avoid vancomycin plus VSL was not cost-effective in critically ill patients with renal failure. More studies are needed to understand if linezolid implementation may be cost-effective in different scenarios.Brazilian Journals Publicações de Periódicos e Editora Ltda.2021-08-24info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/3492510.34119/bjhrv4n4-275Brazilian Journal of Health Review; Vol. 4 No. 4 (2021); 17974-17987Brazilian Journal of Health Review; v. 4 n. 4 (2021); 17974-179872595-6825reponame:Brazilian Journal of Health Reviewinstname:Federação das Indústrias do Estado do Paraná (FIEP)instacron:BJRHporhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/34925/pdfCopyright (c) 2021 Brazilian Journal of Health Reviewinfo:eu-repo/semantics/openAccessTuon, Felipe FranciscoPepes, AllanaOliveira, Dayana Dos SantosZequinao, TiagoCruz, June Alisson WestarbTelles, João Paulo2021-09-16T17:41:44Zoai:ojs2.ojs.brazilianjournals.com.br:article/34925Revistahttp://www.brazilianjournals.com/index.php/BJHR/indexPRIhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/oai|| brazilianjhr@gmail.com2595-68252595-6825opendoar:2021-09-16T17:41:44Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)false
dc.title.none.fl_str_mv Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida real
title Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida real
spellingShingle Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida real
Tuon, Felipe Francisco
Vancomycin
Linezolid
Antimicrobial Stewardship
Economy.
title_short Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida real
title_full Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida real
title_fullStr Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida real
title_full_unstemmed Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida real
title_sort Cost-minimization in Health: Linezolid versus vancomycin with serum monitoring in patients with incipient renal failure – a simulation and real-life / Minimização de custos em Saúde: Linezolida versus vancomicina com monitoramento sérico em pacientes com insuficiência renal incipiente - uma simulação e vida real
author Tuon, Felipe Francisco
author_facet Tuon, Felipe Francisco
Pepes, Allana
Oliveira, Dayana Dos Santos
Zequinao, Tiago
Cruz, June Alisson Westarb
Telles, João Paulo
author_role author
author2 Pepes, Allana
Oliveira, Dayana Dos Santos
Zequinao, Tiago
Cruz, June Alisson Westarb
Telles, João Paulo
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Tuon, Felipe Francisco
Pepes, Allana
Oliveira, Dayana Dos Santos
Zequinao, Tiago
Cruz, June Alisson Westarb
Telles, João Paulo
dc.subject.por.fl_str_mv Vancomycin
Linezolid
Antimicrobial Stewardship
Economy.
topic Vancomycin
Linezolid
Antimicrobial Stewardship
Economy.
description Vancomycin serum levels (VSL) were measured to prevent dose-dependent side effects.  However, the cost of VSL is high, therefore in some cases alternative antibacterial treatments, such as linezolid, can be used. The aim of this study was to perform an economic analysis of the cost of linezolid compared to vancomycin plus therapeutic drug monitoring. This is an ecological, retrospective, quantitative study, conducted in a Brazilian public university hospital. The study period was from January 2018 to January 2019.  First part from January/18 - July/18 based on pre-linezolid data (T1) and another after the introduction of linezolid from August/18 - January/19 (T2). A breakeven analysis to vancomycin substitution was performed following 3 scenarios: (i) in all patients, (ii) in critically ill patients with renal failure or (iii) only in patients in hemodialysis. The DDD/1000-patients day, MRSA incidence, costs with VSL, as well as the costs of drugs (vancomycin and linezolid) and infusion kits were evaluated. Vancomycin was substituted in critically ill patients with renal failure from T1 to T2. The incidence of MRSA infections did not vary between T1 and T2. Vancomycin consume maintained constant (p=0.157); while linezolid consuming increased (0 DDD/1000PD versus 33.4 DDD/1000PD; p=0.002). Vancomycin and linezolid costs was lower in T1 than T2 (USD 9202,00 versus 11331,00; p=0.015). Linezolid implementation as a strategy to avoid vancomycin plus VSL was not cost-effective in critically ill patients with renal failure. More studies are needed to understand if linezolid implementation may be cost-effective in different scenarios.
publishDate 2021
dc.date.none.fl_str_mv 2021-08-24
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/34925
10.34119/bjhrv4n4-275
url https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/34925
identifier_str_mv 10.34119/bjhrv4n4-275
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/34925/pdf
dc.rights.driver.fl_str_mv Copyright (c) 2021 Brazilian Journal of Health Review
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Brazilian Journal of Health Review
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Brazilian Journals Publicações de Periódicos e Editora Ltda.
publisher.none.fl_str_mv Brazilian Journals Publicações de Periódicos e Editora Ltda.
dc.source.none.fl_str_mv Brazilian Journal of Health Review; Vol. 4 No. 4 (2021); 17974-17987
Brazilian Journal of Health Review; v. 4 n. 4 (2021); 17974-17987
2595-6825
reponame:Brazilian Journal of Health Review
instname:Federação das Indústrias do Estado do Paraná (FIEP)
instacron:BJRH
instname_str Federação das Indústrias do Estado do Paraná (FIEP)
instacron_str BJRH
institution BJRH
reponame_str Brazilian Journal of Health Review
collection Brazilian Journal of Health Review
repository.name.fl_str_mv Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)
repository.mail.fl_str_mv || brazilianjhr@gmail.com
_version_ 1797240065913520128